ArticleIn vivo (Athens, Greece)
High Expression of Pregnancy Specific Beta-1-glycoprotein 1 Is Associated With Poor Gastric Cancer Prognosis.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Global burden and future trends of gastric cancer in women of reproductive age: estimates from the GBD 2021 Study, 1990-2050.Frontiers in oncology · 2025Article
- Identification of Prognostic and Immune Characteristics of Two Lung Adenocarcinoma Subtypes Based on TRPV Channel Family Genes.The Journal of membrane biology · 2024Article
- Pregnancy and Gastric Cancer: A Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimPregnancy specific beta-1-glycoprotein 1 (PSG1) is a member of the immunoglobulin superfamily and associated with carcinoembryonic antigens. It has been reported to be highly expressed in variety of cancers. However, the role of PSG1 in gastric cancer remains unclear. The aim of our study was to examine the clinical significance and functional role of PSG1 in gastric cancer. MATERIALS AND
methodsWe analyzed the association between PSG1 expression levels and clinicopathological features using Kaplan-Meier survival curves and publicly available microarray data. In gastric cancer cell lines, PSG1 expression levels were detected by polymerase chain reaction and western blot analysis. The functional role of PSG1 on the proliferation, migration and invasive abilities were also investigated using PSG1 siRNA or an over-expression plasmid vector through WST, transwell migration and invasion assays.
resultsPSG1 expression levels were higher in gastric cancer patient tissues than in normal gastric tissues. Increased expression of PSG1 was associated with poor patient prognosis. Knockdown of PSG1 inhibited cell proliferation, migration, and invasion in gastric cancer cells. In contrast, over-expression of PSG1 enhanced cell proliferation, migration, and invasion.
conclusionPSG1 is up-regulated in gastric cancer and may serve as an oncogene that promotes cell proliferation, migration, and invasion. PSG1 is an independent prognostic factor for the progression of gastric cancer and may be a potential biomarker and therapeutic target for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.